市場調査報告書：抗体医薬標的と乳癌、前立腺癌

Abstract

In this triple analysis report BioSeeker Group has analyzed three major and intertwined areas of cancer R&D, Antibody drug target, Breast- and Prostate cancer, which are all subjects to an extensive number of innovative drug candidates. This extensive 380+ pages report compiles and analyzes in parallel the progress concerning drug development and competitive situation in Antibody drug targeting and further give an in depth analysis in two key oncology areas; Breast- and Prostate cancer. The report will not only provide a framework but also a careful identification and evaluation of drug candidates, technologies and competitors. There are currently more than 400 antibody based drugs in development for the treatment of cancer. BioSeeker has surveyed these antibodies and identified 132 antibody drug targets, belonging to 220 antibody drugs. In all they range from preclinical development to established therapy leaders in the market place. In total more than 420 clinical trials are included in this analysis, covering more than 30 different cancer indications plus diagnosis and supportive care.

Drug targets and their associated antibodies have been analyzed by BioSeeker according to:

34 Different molecular functions of target
13 Major signaling pathways
Cancer stem cells
Conjugated antibodies
Therapeutic effects: Anti-angiogenesis, Apoptosis and Protein Kinase Inhibition
31 Targeted cancer indications
Availability of expression profiles of targets in human tissues, cancer tissues, established cell lines and primary cell cultures
Antibody therapeutic companies

In breast cancer we have identified 170 drug candidates in clinical stage of development and more than 100 companies are involved in the development of these drugs. As a treatment for breast cancer hormone modifying therapies together with different chemotherapeutic schedules have been of highest interest during the last years of progress. A vast amount of new clinical research data has emerged and several new clinical trials have been iniated and others generated new results. Protein kinase inhibitors and epothilones have generated substantial amount of new research data in this field. But, other strategies seem not successful and we are still waiting new information regarding their progress. In prostate cancer we have identified 127 drug candidates in phase II or III stage of development and more than 85 companies are involved in the development of these drugs. Two of the most successful strategies are apoptosis inducers and cell based vaccines. Three out of 10 late stage candidates are apoptosis inducers. Cell based vaccines has been tried for some time but has so far failed to generate substantial improvements.

Breast and Prostate Cancer Highlights

Thorough examination of status and impact of several novel drugs in development
Discussion of the challenges in current and future treatment strategies
Anticancer pipeline of most companies in the field

Key reasons to read this report

This report serves as a serious reference for professionals interested in the development of oncology drug targets and selection/validation of targeting strategies.
Explore the strengths and weaknesses associated with compounds in clinical development. Scientific rationale for most novel therapeutics in breast- and prostate cancer R&D, and the results of clinical trials to date
Gain insight into the current challenges and commercial opportunities associated with breast- and prostate cancer therapy

1. Executive Summary

2. Methodologies

3. Table of Contents

3.1 List of Figures
3.2 List of Tables
3.3 List of Boxes

4. Antibody Drug Target Analysis in Oncology: What and Where Are We Targeting?

5. Antibody Drug Targets by Molecular Function

5.1 Carboxypeptidase Activity Targets
5.2 Catalytic Activity Targets
5.3 Cell Adhesion Molecule Activity Targets
5.4 Chaperone Activity Targets
5.5 Chemokine Activity Targets
5.6 Cofactor Binding Targets
5.7 Complement Activity Targets
5.8 Cytokine Activity Targets
5.9 DNA Topoisomerase Activity Targets
5.10 Extracellular Matrix Structural Constituent Targets
5.11 G-protein Coupled Receptor Activity Targets
5.12 Growth Factor Activity Targets
5.13 Hormone Activity Targets
5.14 Hydrolase Activity Targets
5.15 Intracellular Ligand-gated Ion Channel Activity Targets
5.16 Metallopeptidase Activity Targets
5.17 MHC Class I Receptor Activity Targets
5.18 Molecular Function Unknown Targets
5.19 Oxidoreductase Activity Targets
5.20 Peptide Hormone Targets
5.21 Protease Inhibitor Activity Targets
5.22 Protein Binding Targets
5.23 Receptor Activity Targets
5.24 Receptor Binding Targets
5.25 Receptor Signaling Complex Scaffold Activity Targets
5.26 Receptor Signaling Protein Tyrosine Phosphatase Activity Targets
5.27 RNA-directed DNA polymerase Activity Targets
5.28 Serine-type Peptidase Activity Targets
5.29 T Cell Receptor Activity Targets
5.30 Translation Regulator Activity Targets
5.31 Transmembrane Receptor Activity Targets
5.32 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets
5.33 Transporter Activity Targets
5.34 Unclassified Targets

6. Antibody Drugs Targeting Signaling Pathways

6.1 Alpha6 Beta4 Integrin Signaling Pathway
- 6.1.1 Description of Pathway
- 6.1.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type
6.2 Androgen Receptor Signaling Pathway
- 6.2.1 Description of Pathway
- 6.2.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type
6.3 B Cell Receptor Signaling Pathway
- 6.3.1 Description of Pathway
- 6.3.2 Antibody Drugs by Target, Developmental Stage and Cancer Type
6.4 EGFR1 Signaling Pathway
- 6.4.1 Description of Pathway
- 6.4.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type
6.5 IL-2 Signaling Pathway
- 6.5.1 Description of Pathway
- 6.5.2 Antibody Drugs by Target, Developmental Stage and Cancer Type
6.6 IL-4 Signaling Pathway
- 6.6.1 Description of Pathway
- 6.6.2 Antibody Drugs by Target, Developmental Stage and Cancer Type
6.7 IL-6 Signaling Pathway
- 6.7.1 Description of Pathway
- 6.7.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type
6.8 Kit Receptor Signaling Pathway
- 6.8.1 Description of Pathway
- 6.8.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type
6.9 Notch Signaling Pathway
- 6.9.1 Description of Pathway
- 6.9.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type
6.10 T Cell Receptor Signaling Pathway
- 6.10.1 Description of Pathway
- 6.10.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type
6.11 TGF-beta Receptor Signaling Pathway
- 6.11.1 Description of Pathway
- 6.11.2 Antibody Drugs byTarget, Developmental Stage, and Cancer Type
6.12 TNF-alpha Signaling Pathway
- 6.12.1 Description of Pathway
- 6.12.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type
6.13 Wnt Signaling Pathway
- 6.13.1 Description of Pathway
- 6.13.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type

7.Antibodies Targeting Cancer Stem Cells

8.Targets of Antibody Conjugates

9.Antibody Drug Targets by Three Major Non Immunological Therapeutic Effects

9.1 Anti-Angiogenesis
9.2 Apoptosis
9.3 Protein Kinase Inhibitors

10. Antibody Targets and Drugs by Cancer Indications

10.1 Basal Cell Cancer
10.2 Biliary Cancer
10.3 Bladder Cancer
10.4 Bone Cancer
10.5 Brain Cancer
10.6 Breast Cancer
10.7 Cervical Cancer
10.8 Cervical Dysplasia
10.9 Colorectal Cancer
10.10 Endometrial Cancer
10.11 Esophageal Cancer
10.12 Fallopian Tube Cancer
10.13 Gastrointestinal Cancers
10.14 Head and Neck Cancer
10.15 Leukemias
10.16 Liver Cancer
10.17 Lung Cancers
10.18 Lymphomas
10.19 Melanoma
10.20 Mesothelioma
10.21 Myelodysplastic syndrome
10.22 Myelomas
10.23 Nasopharyngeal Cancer
10.24 Oesophageal Cancer
10.25 Ovarian Cancer
10.26 Pancreatic Cancer
10.27 Peritoneal Cancer
10.28 Prostate Cancer
10.29 Renal Cancers
10.30 Sarcomas
10.31 Thyroid Cancer

11. Expression Profiles of Antibody Drug Targets

11.1 Human Tissues and Cancer Tissues
11.2 Cancer Lines and Cells

12. Breast Cancer: An Introduction

12.1 Disease Definitions
12.2 Etiology
12.3 Epidemiology
12.4 Prognosis

13. Current Treatment Strategies of Breast cancer

13.1 Localized Disease
13.2 Advanced Disease

14. Progress in Current Breast Cancer Treatment Strategies

14.1 Hormone Based Therapies
14.2 Antibodies
14.3 Chemotherapy
14.4 Chemotherapy

15. Key Therapeutic Strategies for Future Breast Cancer Therapies

15.1 Therapeutic Type, Targets & Mechanisms

16. Competitive Landscape in Breast Cancer Drug Development: The Late Stage Pipeline

16.1 The Epothilones
16.2 Cell Cycle & Apoptosis
16.3 Protein Kinase Inhibitors
16.4 Immunotherapy

17. Current Drug Development for Breast Cancer: The Early Stage Pipeline

17.1 DNA Targeting
17.2 FTIs
17.3 Antisense
17.4 New Hormone Modulators
17.5 Other

18 Prostate Cancer: An Introduction

18.1 Disease Definitions
18.2 Etiology & Pathophysiology
18.3 Epidemiology
18.4 Prognosis

19. Current Prostate Cancer Treatment Strategies

19.1 Localized Disease
19.1.1 Locally Advanced Prostate Cancer
19.2 Metastatic Prostate Cancer
- 19.2.1 Hormone-Sensitive Metastatic Prostate Cancer
- 19.2.2 Hormone-Refractory or Recurrent Metastatic Prostate Cancer

20. Progress in Current Prostate CancerTreatment Strategies

20.1 Long-Term Follow-up Data not yet Been Published
20.2 Significant Reduced Risk of Distant Metastases
20.3 Adverse Events
20.4 No Difference in Overall Survival
20.5 Cross-over Design an Optimal Option?
20.6 Death due to Liver Failure
20.7 Survival Benefit
20.8 Subdermal Implant
20.9 No FDA Approval
20.10 No Improvement in 5-year Disease-Free Survival
20.11 Effective Secondary Hormonal Therapy?
20.12 Synery in Combination

21. Key Therapeutic Strategies for Future Prostate Cancer Therapies

21.1 Therapeutic Type, Targets & Mechanisms

22. Competitive Landscape in Prostate Cancer Drug Development: The Late Stage Pipeline

22.1 Reduced Prostate Cancer Risk
22.2 High Activity in Metastatic AIPC Patients
22.3 Absence of Severe Toxicities
22.4 Waiting for Data
22.5 Probability of Regulatory Approval?
22.6 Co-development and License Agreement
22.7 Improves Predicted Survival?
22.8 Slow Progress & Development Partners
22.9 Exclusive License Agreement

23. Current Prostate Cancer Drug Development: The Early Stage Pipeline

23.1 New Data?
23.2 Terminated Study
23.3 More Than 50% PSA decline
23.4 Safety and Tolerability
23.5 Terminated?
23.6 Marker of Drug Effect
23.7 Preliminary Results for a Tyrosine Kinase Inhibitor
23.8 No Activity in Monotherapy
23.9 Dramatic Disappearance of Bone Metastatic Lesions
23.10 PSA Response - Anthracycline

抗体医薬標的と乳癌、前立腺癌

Antibody Drug Targets and Focus on Breast- & Prostate Cancer

Abstract

Drug targets and their associated antibodies have been analyzed by BioSeeker according to:

Breast and Prostate Cancer Highlights

Key reasons to read this report

Table of Contents

1. Executive Summary

2. Methodologies

3. Table of Contents

4. Antibody Drug Target Analysis in Oncology: What and Where Are We Targeting?

5. Antibody Drug Targets by Molecular Function

6. Antibody Drugs Targeting Signaling Pathways

7.Antibodies Targeting Cancer Stem Cells

8.Targets of Antibody Conjugates

9.Antibody Drug Targets by Three Major Non Immunological Therapeutic Effects

10. Antibody Targets and Drugs by Cancer Indications

11. Expression Profiles of Antibody Drug Targets

12. Breast Cancer: An Introduction

13. Current Treatment Strategies of Breast cancer

14. Progress in Current Breast Cancer Treatment Strategies

15. Key Therapeutic Strategies for Future Breast Cancer Therapies

16. Competitive Landscape in Breast Cancer Drug Development: The Late Stage Pipeline

17. Current Drug Development for Breast Cancer: The Early Stage Pipeline

18 Prostate Cancer: An Introduction

19. Current Prostate Cancer Treatment Strategies

20. Progress in Current Prostate CancerTreatment Strategies

21. Key Therapeutic Strategies for Future Prostate Cancer Therapies

22. Competitive Landscape in Prostate Cancer Drug Development: The Late Stage Pipeline

23. Current Prostate Cancer Drug Development: The Early Stage Pipeline

24. Disclaimer

25. Drug Index

26. Company Index

27. Appendix I: Antibody Targets by Companies